Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana

Frederica Dedo Partey, Abigail Naa Adjorkor Pobee, Isaac Kumi Damptey, Francis Osei, M. M. A. K. Owusu-Amponsah, Y. A. A. Ansah, Carrie Ye, Steven B. Bradfute, Ivy Hurwitz, Peter K. Quashie, Michael F. Ofori, Aija Kusi, Douglas J. Perkins, Gordon A. AwandareExperimental 2025 · DOI

Abstract

COVID-19 booster vaccinations are essential for addressing waning immunity and the emergence of new variants. In sub-Saharan Africa, data on vaccine-induced immunity remains limited. This study examined functional antibody responses against various SARS-CoV-2 variants before and after booster vaccinations in Ghanaian adults between November 2022 and February 2023. While natural exposure (measured by N antigen antibodies) was widespread across both vaccinated and unvaccinated groups, RBD-specific IgG levels were significantly higher in vaccinated individuals, except for the Omicron variant. Booster effectiveness varied by platform: Pfizer-BioNTech elicited broad responses across all variants, whereas the J&J booster showed limited gains against Delta and Omicron. Extended intervals between doses may have enhanced antibody quality through affinity maturation, though Omicron continues to demonstrate significant immune evasion.

Introduction

The global effort to combat COVID-19 relies heavily on booster vaccinations to maintain protection against evolving variants. However, there is a significant data gap regarding vaccine performance in sub-Saharan Africa (SSA), where unique environmental factors and high natural exposure rates may influence immune responses. This study addresses this gap by evaluating the functional activity of vaccine-induced antibodies in a cohort of adults in Ghana, comparing different vaccine platforms against a backdrop of high community transmission.

Methods

Researchers conducted a longitudinal study of 122 adults (86 vaccinated, 36 unvaccinated) in Ghana. Immune responses were assessed using three primary methods:

  1. Indirect ELISA: Quantified IgG antibodies against the Nucleocapsid (N) protein and the Spike Receptor Binding Domain (RBD) of five variants (Wild-type, Alpha, Beta, Delta, and Omicron).
  2. ACE-2 Inhibition Assay: Measured the ability of plasma antibodies to block the interaction between the viral spike protein and human ACE-2 receptors.
  3. Plaque Reduction Neutralization Test (PRNT80): Used live SARS-CoV-2 virus to determine the actual neutralizing capacity of the participants' plasma.

Results

Analysis of N-antigen-specific antibodies revealed that natural exposure was nearly universal, with similar levels found in both vaccinated and unvaccinated individuals. In contrast, RBD-specific IgG levels were significantly higher in vaccinated participants than in those with only natural exposure for most variants, though this difference was less pronounced for Omicron.

Figure 5: Normalized ELISA O.D. for N antigen (A) and various RBD variants (B-F) across different vaccine dose counts.

The study highlighted a clear divergence in booster performance between vaccine types. The Pfizer-BioNTech (mRNA) booster significantly increased RBD IgG levels against all tested variants. Conversely, the Johnson & Johnson (adenoviral) booster failed to significantly increase defenses against the Delta and Omicron variants. While live virus neutralization against the Wild-type virus improved significantly after boosting, neutralization of Omicron remained stable, indicating persistent evasion by this variant.

Discussion and Conclusion

A notable finding was the potential benefit of the extended intervals between vaccine doses observed in this cohort (averaging over 450 days). Such delays may allow for better affinity maturation of B-cells, resulting in higher-quality antibodies. However, the muted response to Omicron remains a concern, suggesting that current boosters may have reached a ceiling of effectiveness against highly mutated variants.

Limitations of the study include a relatively small and young sample size. Future research should investigate long-term immunity durability and the impact of regional co-infections, such as malaria, on vaccine-induced responses in African populations. These findings are crucial for tailoring public health policies and booster strategies in resource-limited settings.

Summary updated

Abstract

COVID-19 booster vaccinations are needed to enhance waning immunity and the emergence of new variants. In Africa, where COVID-19 vaccine coverage is low, there is a paucity of data on COVID-19 vaccine-induced immunity, particularly in the post-omicron era. This study examined the functional activity of vaccine-induced antibody responses against different variants before and after booster vaccinations in adults in Ghana, between November 2022 and February 2023. SARS-CoV-2 nucleocapsid protein and spike receptor binding domain (RBD) antigen-specific IgG levels against different viral variants were determined in plasma. Plasma was tested for the ability to inhibit ACE-2 binding to RBD variants. N antigen-specific antibody levels were comparable between vaccinated and previously infected, but unvaccinated individuals. However, RBD IgG levels before booster vaccinations were significantly higher in vaccinated participants than in exposed, unvaccinated individuals, except for Omicron. RBD IgG levels remained unchanged after the booster in participants with three prior vaccine doses but were significantly higher than in those with only primary vaccinations (Wild type p = 0.0315, Alpha p = 0.0090, Beta p = 0.0020, Delta p = 0.0040) except Omicron (p = 0.09). Participants who received the Pfizer-BioNTech vaccine showed a significant increase (p < 0.05) in RBD IgG levels against all tested variants from baseline to 3 months. In contrast, participants who received the J&J vaccine only showed a significant increase in RBD IgG to Wildtype (p = 0.04), Alpha (p < 0.0001), and Beta (p < 0.0001), but not Delta and Omicron. The inhibition of ACE-2 binding and live virus neutralization titers were significantly higher in vaccinated individuals than in unvaccinated individuals before the booster (p < 0.001). Virus neutralization titers against Wildtype were significantly high 3 months after booster (p < 0.001), but neutralization titers against Omicron remained stable from baseline to 3 months after booster. Extended interval between vaccinations may enhance vaccine-induced antibody responses.
BibTeX
@inproceedings{partey2025functional,
  author = {Frederica Dedo Partey and Abigail Naa Adjorkor Pobee and Isaac Kumi Damptey and Francis Osei and M. M. A. K. Owusu-Amponsah and Y. A. A. Ansah and Carrie Ye and Steven B. Bradfute and Ivy Hurwitz and Peter K. Quashie and Michael F. Ofori and Aija Kusi and Douglas J. Perkins and Gordon A. Awandare},
  title = {{Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana}},
  booktitle = {Experimental},
  year = {2025},
  doi = {10.3389/ebm.2025.10440},
}
Figure